PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
Low Confidence Animal StudyPrimary source: [Open]
Linked compounds: kpv
Outcomes summary
Study combining cell models and mouse colitis models, reporting that tripeptide KPV can be transported by PepT1 and is associated with reduced inflammatory signaling and cytokine expression in the experimental settings.
Limitations
Preclinical models; effects may be context-dependent; does not establish human efficacy or safety for inflammatory bowel disease.
Notes
Primary source: PMID 18061177.